The overall goal of this protocol is to evaluate the biodistribution of \[18F\]MNI-968 as a D1 receptor targeted radiopharmaceutical.
The overall goal of this protocol is to evaluate the biodistribution of \[18F\]MNI-968 as a D1 receptor targeted radiopharmaceutical. The specific objectives are: * To determine the radiation dosimetry of \[18F\]MNI-968 * To assess the safety and tolerability of a single dose of \[18F\]MNI-968
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
6
Healthy volunteers recruited for the study will undergo a single \[18F\]MNI-968 injections and PET scans.
Molecular NeuroImaging, LLC
New Haven, Connecticut, United States
Whole body tomographic PET images will be obtained for 6 healthy volunteers, and reviewed visually for assessment of body organ distribution of radioactivity.
Volumes of interest (VOI) will be placed on the visually identified source organs, and subsequently used for all the study PET frames. Activity within these volumes of interest is expressed in units of total radioactivity (kBq). Radioactivity will be corrected for body attenuation, but not for decay, and time activity data (TAC) generated for each source organ.
Time frame: 2 Months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.